If you or a loved one is navigating a bleeding disorder, you’ve probably noticed that care isn’t always straightforward. From specialized treatments to coordinated support, managing these conditions can feel overwhelming. That’s where Hemophilia Treatment Centers (HTCs) come in.
In this article, we’ll explore what HTCs are, who they serve, why their comprehensive care model makes a real difference, and how CIBD puts these principles into practice to support patients’ health, wellbeing, and quality of life.
What Is a Hemophilia Treatment Center (HTC)?
A Hemophilia Treatment Center is a nationally recognized center of excellence providing specialized, coordinated care for individuals with hemophilia and other inherited bleeding disorders.
HTCs are federally supported and based on a comprehensive care model, meaning patients receive whole-person support from a dedicated team that understands the medical, emotional, and social realities of living with a bleeding disorder.
Who Do HTCs Serve?
HTCs support individuals across the full spectrum of inherited bleeding disorders, including:
- Hemophilia A and Hemophilia B
- Von Willebrand disease
- Rare factor deficiencies
- Other inherited bleeding disorders
Nationwide, HTCs care for nearly 28,000 people living with bleeding disorders and serve patients of all ages, backgrounds, and stages of life.
What Makes HTC Care Different?
HTCs stand apart because of their team-based, coordinated approach to care. Patients receive support from a multidisciplinary team of hematologists, nurses, social workers, psychologists, and physical therapists who work together to manage treatment, monitor health, and provide guidance every step of the way. This ensures care is connected, communication is clear, and patients feel supported throughout their journey.
HTCs are also nationally recognized as the gold standard in bleeding disorder care. The National Bleeding Disorders Foundation recommends that individuals with bleeding disorders receive regular care through a federally-funded HTC, highlighting the value of specialized, comprehensive care models.
Better Care Leads to Better Outcomes
HTCs don’t just feel different; they produce real results. Patients treated at HTCs experience 40% lower mortality rates compared to those who are not treated at HTCs, even though these centers often care for patients with more complex or severe conditions.
HTC care is also associated with fewer complications, better joint health, reduced hospitalizations, stronger continuity of care, improved long-term outcomes, and higher overall quality of life.
HTCs provide access to the latest treatments, research, and clinical trials, ensuring that scientific progress translates into real-life benefits. From advanced infusion therapies to emerging treatment models, they help patients live healthier, more supported lives.
To learn more about how treatment has evolved from early therapies to today’s breakthroughs, explore our blog post on Bleeding Disorders Awareness Month: History, Facts, and Treatment Advancements.
Expanding Access Through the 340B Program
HTCs play a critical role in making treatment more accessible through participation in the 340B federal drug pricing program.
This program allows eligible healthcare organizations, including HTCs like CIBD, to purchase medications at reduced cost. These savings are reinvested directly into patient care and services, helping to support:
- Comprehensive care teams
- Care coordination
- Patient education
- Access to specialty services
- Financial assistance
The 340B program helps sustain the comprehensive care model that makes HTCs unique. It ensures that care remains accessible, sustainable, and centered on patient needs, not just treatment delivery.
Comprehensive Care at CIBD
At CIBD, comprehensive, patient-centered care is the foundation of everything we do. Our approach reflects the core principles of HTC care: coordinated services, multidisciplinary teams, advanced treatment access, and long-term support for individuals and families.
During Bleeding Disorders Awareness Month and beyond, we remain committed to building systems of care that don’t just treat conditions, but support lives, dignity, stability, and futures.
Bleeding disorders require more than treatment.
They require care systems that truly understand them.
That’s why HTCs matter.